Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215

Neumora Therapeutics, Inc.

2025-Q2 EPS reported -$0.75

Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.
Q2 net loss $52.7M vs $58.7M in Q2 2024; R&D expense fell to $38.7M from $48.6M.
Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-861; data expected Q1 2026.
Prioritized obesity as lead indication for NLRP3 inhibitor NMRA-215; preclinical DIO data expected in 2025, clinical start Q1 2026.
Expects up to six clinical data readouts over next 18 months including navacaprant Phase 3 (1H 2026) and NMRA-511 Phase 1b (end 2025).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.